Back
Full-text
Journal article

Carbapenemase-Producing Organisms: A Global Scourge.

  • Bonomo RA Medical Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio.
  • Burd EM Department of Pathology and Laboratory Medicine, Atlanta, Georgia.
  • Conly J Departments of Medicine, Pathology and Laboratory Medicine, Microbiology, Calgary, Alberta, Canada.
  • Limbago BM Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Poirel L Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science, University of Fribourg, Switzerland.
  • Segre JA Microbial Genomics Section, Translational and Functional Genomics Branch, National Human Genome Research Institute, Bethesda, Maryland.
  • Westblade LF Department of Pathology and Laboratory Medicine, New York, New York.
Show more…
  • 2017-11-23
Published in:
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. - 2018
Anti-Bacterial Agents
Bacterial Proteins
Carbapenem-Resistant Enterobacteriaceae
Carbapenems
Enterobacteriaceae
Enterobacteriaceae Infections
Global Health
Humans
Prevalence
beta-Lactamases
English The dramatic increase in the prevalence and clinical impact of infections caused by bacteria producing carbapenemases is a global health concern. Carbapenemase production is especially problematic when encountered in members of the family Enterobacteriaceae. Due to their ability to readily spread and colonize patients in healthcare environments, preventing the transmission of these organisms is a major public health initiative and coordinated international effort are needed. Central to the treatment and control of carbapenemase-producing organisms (CPOs) are phenotypic (growth-/biochemical-dependent) and nucleic acid-based carbapenemase detection tests that identify carbapenemase activity directly or their associated molecular determinants. Importantly, bacterial isolates harboring carbapenemases are often resistant to multiple antibiotic classes, resulting in limited therapy options. Emerging agents, novel antibiotic combinations and treatment regimens offer promise for management of these infections. This review highlights our current understanding of CPOs with emphasis on their epidemiology, detection, treatment, and control.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.rero.ch/global/documents/80634
Statistics
Document views: 21 File downloads:
  • Full-text: 0